Legal Disclaimer

This page provides general legal orientation for Japan, not legal advice. Regulations change frequently. Always verify current rules with PMDA and consult a qualified professional.

Peptide Legal Status in Japan

Moderate

Japan regulates pharmaceuticals through MHLW and PMDA under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (PMD Act). GLP-1 agonists are approved — Ozempic since 2018, Rybelsus since 2020, Wegovy since March 2023, and Mounjaro since September 2022. Japan's National Health Insurance (NHI) covers diabetes indications but weight management coverage is limited (Wegovy was added to NHI in February 2024 under strict criteria: BMI ≥35, or BMI ≥27 with comorbidities). Personal import of peptides requires a Yakkan Shoumei import certificate. Online medical consultation is permanently authorized under 2022 MHLW guidelines, but first-time GLP-1 prescriptions are expected to follow appropriate clinical assessment.

Regulator

PMDA (Pharmaceuticals and Medical Devices Agency) / MHLW (Ministry of Health, Labour and Welfare) — Official website

Key Facts

Regulatory Stance
moderate
Compounding Allowed
Yes
Telehealth Prescribing
Yes

Compounding Pharmacy Rules

Pharmacy compounding (院内製剤 — in-hospital preparations) is permitted under the PMD Act. Compounding is primarily conducted in hospital pharmacies for individual patients with valid prescriptions. Community pharmacy compounding is more limited than in Western countries. GMP standards apply.

Telehealth Prescribing

Online medical consultation (オンライン診療) was permanently authorized under MHLW guidelines revised in March 2022. First-visit online consultations are now permitted with appropriate safeguards. However, MHLW issued warnings in 2023 against illegal online-only prescribing of GLP-1s for weight loss by aesthetic clinics — initial prescriptions should follow proper clinical assessment standards.

Peptide Categories in Japan

Approved

Semaglutide — Ozempic (approved March 2018 for T2D), Rybelsus (approved September 2020, oral), Wegovy (approved March 2023 for weight management). Tirzepatide — Mounjaro (approved September 2022 for T2D). Liraglutide — Victoza (T2D), Saxenda (weight management). All MHLW/PMDA-approved, prescription-only. Wegovy NHI coverage from February 2024: limited to BMI ≥35 or BMI ≥27 with ≥2 comorbidities.

Research / Unapproved

BPC-157, TB-500, GHRPs — not approved as pharmaceuticals. Import and sale of unapproved drugs is regulated under the PMD Act. Japan enforces strict personal import rules: a Yakkan Shoumei (import certificate) is required from the Regional Bureau of Health and Welfare before importing any drug, including peptides. Customs will detain unapproved imports without the certificate.

Banned / Restricted

Unapproved pharmaceuticals. Personal import without Yakkan Shoumei. Controlled substances under the Narcotics and Psychotropics Control Act. MHLW and Customs (税関) conduct joint enforcement against illegal pharmaceutical imports.

Key Legislation

  • Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (PMD Act, Act No. 145 of 1960)
  • Medical Care Act
  • Medical Practitioners Act
  • Narcotics and Psychotropics Control Act

Peptides in Japan: FAQ

Sources

Peptide Laws in Other Countries

United KingdomCanadaAustraliaEuropean UnionSingaporeUnited Arab EmiratesNew ZealandGermanyNetherlandsFranceSpainHong KongSouth Korea